The FDA approved nivolumab plus hyaluronidase (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo, Bristol Myers Squibb) indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab (Yervoy, Bristol Myers Squibb) combination therapy, or in combination with chemotherapy or cabozantinib.
The approval includes indications for colorectal cancer, hepatocellular carcinoma, esophageal carcinoma,